Neumora Therapeutics Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation

Reuters01-05

Neumora <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation

Neumora Therapeutics Inc. has announced positive results from its Phase 1b signal-seeking study of NMRA-511, a selective vasopressin 1a receptor antagonist, in patients with agitation associated with Alzheimer’s disease. The study demonstrated a clinically meaningful reduction of 15.7 points on the mean Cohen-Mansfield Agitation Inventory (CMAI) total score and showed a favorable safety and tolerability profile, with treatment-emergent adverse events mostly mild to moderate and a low discontinuation rate. The company plans to advance NMRA-511 development by initiating a multiple ascending dose extension study and formulation development for once-daily extended-release dosing in 2026, as well as a Phase 2/3 dose-ranging study. These findings were presented during a company webcast and conference call held on January 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619496-en) on January 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601883404?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601883404","market":"us","top_or_hot":-1,"title":"Neumora Therapeutics Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Neumora Therapeutics Inc. has announced positive results from its Phase 1b signal-seeking study of NMRA-511, a selective vasopressin 1a receptor antagonist, in patients with agitation associated with Alzheimer’s disease. The study demonstrated a clinically meaningful reduction of 15.7 points on the mean Cohen-Mansfield Agitation Inventory (CMAI) total score and showed a favorable safety and tolerability profile, with treatment-emergent adverse events mostly mild to moderate and a low discontinuation rate. The company plans to advance NMRA-511 development by initiating a multiple ascending dose extension study and formulation development for once-daily extended-release dosing in 2026, as well as a Phase 2/3 dose-ranging study. These findings were presented during a company webcast and conference call held on January 5, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619496-en) on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neumora Therapeutics Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeumora Therapeutics Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Neumora Therapeutics Inc. has announced positive results from its Phase 1b signal-seeking study of NMRA-511, a selective vasopressin 1a receptor antagonist, in patients with agitation associated with Alzheimer’s disease. The study demonstrated a clinically meaningful reduction of 15.7 points on the mean Cohen-Mansfield Agitation Inventory (CMAI) total score and showed a favorable safety and tolerability profile, with treatment-emergent adverse events mostly mild to moderate and a low discontinuation rate. The company plans to advance NMRA-511 development by initiating a multiple ascending dose extension study and formulation development for once-daily extended-release dosing in 2026, as well as a Phase 2/3 dose-ranging study. These findings were presented during a company webcast and conference call held on January 5, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619496-en) on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NMRA","symbol_name":"Neumora Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL288hS2:1","article_id":"2601883404","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601883404","pubTimestamp":1767612611,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Neumora Therapeutics Inc. has announced positive results from its Phase 1b signal-seeking study of NMRA-511, a selective vasopressin 1a receptor antagonist, in patients with agitation associated with Alzheimer’s disease. The study demonstrated a clinically meaningful reduction of 15.7 points on the mean Cohen-Mansfield Agitation Inventory  total score and showed a favorable safety and tolerability profile, with treatment-emergent adverse events mostly mild to moderate and a low discontinuation rate. The company plans to advance NMRA-511 development by initiating a multiple ascending dose extension study and formulation development for once-daily extended-release dosing in 2026, as well as a Phase 2/3 dose-ranging study. These findings were presented during a company webcast and conference call held on January 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NMRA":"Neumora Therapeutics, Inc.","NDAQ":"纳斯达克OMX交易所","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4007":"制药","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Neumora Therapeutics报告NMRA-511治疗阿尔茨海默病躁动的1b期结果呈阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NMRA":0.9,"NDAQ":0.9},"content_text":"Neumora Therapeutics Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation\n    \n\n        Neumora Therapeutics Inc. has announced positive results from its Phase 1b signal-seeking study of NMRA-511, a selective vasopressin 1a receptor antagonist, in patients with agitation associated with Alzheimer’s disease. The study demonstrated a clinically meaningful reduction of 15.7 points on the mean Cohen-Mansfield Agitation Inventory (CMAI) total score and showed a favorable safety and tolerability profile, with treatment-emergent adverse events mostly mild to moderate and a low discontinuation rate. The company plans to advance NMRA-511 development by initiating a multiple ascending dose extension study and formulation development for once-daily extended-release dosing in 2026, as well as a Phase 2/3 dose-ranging study. These findings were presented during a company webcast and conference call held on January 5, 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619496-en) on January 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601883404","isCrawlerRequest":true}